HOME >> BIOLOGY >> NEWS
Human Genome Sciences announces the discovery of a novel immune stimulant

s recovering from chemotherapy and bone marrow transplantation may often have low levels of antibodies as a result of low numbers of B cells. In such situations antibody deficiency may last from months to years. One potential medical use of BLyS would be to shorten the recovery time for such patients. Another potential use might be to stimulate B cell growth in AIDS patients deficient in B cell production.

Use as a Vaccine Adjuvant
Vaccines work, in part, by inducing the production of antibodies that recognize invading organisms. Used as a vaccine adjuvant, BLyS may enhance the effectiveness of a wide range of vaccine candidates by strengthening the immune response through its ability to stimulate B cell production.

Treatment of B Cell Leukemia and Lymphoma
The discovery of a new growth factor specific for B cells may also lead to new treatments for leukemias and lymphomas that arise from abnormal proliferation of B cells. BLyS interacts with a specific structure on the surface of B cells called a receptor. Drugs that interfere with binding of BLyS to this receptor may kill or at least slow the growth of B cell tumors.

The Discovery of BLyS
BLyS represents the successful application of a new systematic, multi-step approach to drug discovery pioneered by HGS scientists. The first step of this process was to isolate and characterize a virtually complete set of human genes. A task completed at HGS by the end of 1995. The second step was to prepare a subset of human genes, those involved in cell to cell communication for analysis of their potential medical use. Each of these genes is available at HGS as a cDNA capable of producing a full-length protein. The next step in the process was to develop a high throughput system to test the biological function and potential medical utility of each of these proteins. Such a system is now in place at HGS. BLyS, one of the body's signaling molecules was fo
'"/>

Contact: Kate de Santis
Kate_de_Santis@hgsi.com
301-251-6003
Human Genome Sciences, Inc.
9-Jul-1999


Page: 1 2 3 4

Related biology news :

1. Human chromosome 5 final sequence analysis released to public
2. Humans march to a faster genetic drummer than primates, UC Riverside research says
3. Applied Mathematical Models in Human Physiology
4. Human health risks in space flight focus of research internships
5. Human periodontal ligament stem cells isolated for the first time
6. Organization for Human Brain Mapping 2004 Annual Meeting
7. 20 May AAAS lecture: Computers that Respond to Human Emotion
8. Human brain works heavy statistics learning language
9. New Woods Hole Center for Oceans and Human Health established
10. European Society of Human Reproduction and Embryology conference - June 2004
11. Human genome-wide RNAi library for biotech and pharma research

Post Your Comments:
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
(Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the leading ... 2nd generation cell therapy POD® design. The 2nd generation portfolio not only delivers ... new POD® design. , “G-CON first offered our miniPOD CT product line ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
Cached News: